Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies

Arthritis & Rheumatism

Volumn 36, Issue 5, 1993, Pages 620-630

  Strand, Vibeke ^a   Lipsky, Peter E ^b   Cannon, Grant W ^c   Calabrese, Leonard H ^d   Wiesenhutter, Craig ^e   Cohen, Stanley B ^f   Olsen, Nancy J ^g   Lee, Martin L ^h,i   Lorenz, Todd J ⁱ   Nelson, Betty ^b,i   Wolfe, Frederick ^j   Fleischmann, Roy M ^f   Karr, Reynold M ^k   Krick, George H ^l   Medsger, Thomas A ^m   Rigby, William F C ⁿ   Fox, David A ^o   Swartz, Timothy J ^p   Multz, Carter V ^q   Weisman, Michael H ^r  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Kootenei Medical Center ^*  (United States)

^f METROPLEX CLINICAL RESEARCH CENTER   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ XOMA Corporation   (United States)

^j ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l Cedar Medical Center   (United States)

^m UNIVERSITY OF PITTSBURGH   (United States)

ⁿ DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^o UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^p UNIVERSITY OF CHICAGO   (United States)

^q Arthritis Care Center Inc ^*  (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD5; RICIN A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD5; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; IMMUNOTOXINS; MALE; METHOTREXATE; MIDDLE AGE; PROSPECTIVE STUDIES; RICIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0027299097     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780360508     Document Type: Article

References (41)

1. Prolonged thoracic duct drainage in rheumatoid arthritis and systemic lupus erythematosus
2. Lymphocyte involvement in rheumatoid arthritis: studies during thoracic duct drainage
3. Lymphapheresis in rheumatoid arthritis: a randomized trial
4. Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis
5. Clinical and immunological effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis
6. Treatment of intractable rheumatoid arthritis with total lymphoid irradiation
7. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M‐T 151: clinical results and immunopharmacologic effects in an open study, including repeated administration
8. Treatment of rheumatoid arthritis with an anti‐CD4 monoclonal antibody
9. Anti‐CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T cells
10. Immunological effects of high dose administration of anti‐CD4 antibody in rheumatoid arthritis patients
11. Use of anti‐pan T‐lymphocyte ricin A chain immunotoxin in steroid resistant graft versus host disease
12. Treatment of refractory rheumatoid arthritis with antilymphocyte immunotoxin (abstract)
13. Treatment of rheumatoid arthritis with an anti‐CD 5 immunoconjugate: clinical and immunologic findings and preliminary results of re‐treatment
14. Treatment of rheumatoid arthritis with an anti‐CD5 immunoconjugate: final results of phase II studies
15. Treatment of rheumatoid arthritis patients with an anti‐CD5 immunoconjugate
16. Treatment of rheumatoid arthritis with anti‐CD 5: possible synergism between biologic and traditional immunosuppressive therapy
17. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
18. Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti‐T cell immunotoxins in the absence of an added potentiator
19. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo
20. Investigation and prevention of artifactual staining in flow cytometric analyses of whole blood samples from patients treated with H65‐RTA, an anti‐CD5 monoclonal antibody conjugated to ricin A chain
21. Weekly pulse methotrexate in rheumatoid arthritis
22. Long‐term prospective trial of low‐dose methotrexate in rheumatoid arthritis
23. Low dose cyclosporin versus placebo in patients with rheumatoid arthritis
24. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
25. The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritis
26. Methotrexate in rheumatoid arthritis
27. Severe flare of rheumatoid arthritis after discontinuation of long‐term methotrexate therapy
28. Efficacy of low‐dose methotrexate in rheumatoid arthritis
29. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (myochrysine) in the treatment of rheumatoid arthritis
30. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty‐eight‐week randomized, double‐blind trial
31. Methotrexate 1989: the evolving story
32. Long‐term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months
33. Long‐term experience with low dose weekly methotrexate in rheumatoid arthritis
34. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study
35. Long‐term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84‐month update
36. Analysis of immune function and phenotype in RA patients treated with an anti‐CD5 immunoconjugate (abstract)
37. Immunologic assessment during treatment of rheumatoid arthritis with anti‐CD5 immunoconjugate
38. Mechanism of action predicting clinical response in rheumatoid arthritis patients treated with an anti‐CD5 immunoconjugate (abstract)
39. Human anti‐mouse antibody response induced by anti‐CD4 monoclonal antibody therapy in patients with rheumatoid arthritis